Latest Articles

Publication Date
Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.

Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other …

Published: Sept. 7, 2025, midnight
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.

Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …

Published: Sept. 1, 2025, midnight
Safety of current strategies to manage moderate to severe pain in patients with endometriosis.

Medical therapy is crucial in the long-term management of endometriosis, and its clinical efficacy must be balanced with a favorable safety profile.

Published: Aug. 25, 2025, midnight
Natural Pregnancy Following Oocyte Retrieval in a Luteal-Phase Progestin-Primed Ovarian Stimulation (PPOS) Protocol With Concurrent Blastocyst Cryopreservation: A Case Report.

Ovarian stimulation is used in assisted reproductive technology to help infertile couples achieve pregnancy. Luteal-phase stimulation with progestin-primed ovarian stimulation (PPOS) is a practical approach, as it involves oral medication …

Published: Aug. 17, 2025, midnight
Laparoscopic ovarian drilling (LOD) versus Step-up gonadotropin therapy in infertile anovulatory PCOS women resistant to sequential letrozole and gonadotropin-based ovulation induction cycles: a randomized controlled trial.

To study the effect of laparoscopic ovarian drilling (LOD) versus step-up gonadotropin therapy on follicular response in infertile anovulatory PCOS women resistant to sequential Letrozole + HMG (Human Menopausal Gonadotropin) …

Published: Aug. 2, 2025, midnight
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …

Published: July 30, 2025, midnight
Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.

Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …

Published: July 28, 2025, midnight
'Ovariostasis' as the main preventive and therapeutic strategy for gynecological pathologies in women of reproductive age.

Ovariostasis is a reversible and temporary suspension of the cyclic ovarian activity, characterized by anovulation and hypogonadotropinemia (low serum concentrations of FSH and LH), which can be observed in case …

Published: April 3, 2025, midnight
Fertility preservation in women with endometriosis: A retrospective non-Inferiority study comparing Dienogest in the PPOS protocol to antagonist and agonist protocols.

Endometriosis is a common pathology that can lead to a decrease in fertility and is therefore a medical indication for preserving fertility. Traditionally, gonadotropin-releasing hormone (GnRH) antagonist and agonist protocols …

Published: April 3, 2025, midnight
Update on the pathogenesis of endometriosis-related infertility based on contemporary evidence.

Endometriosis, the most prevalent cause of infertility, is associated with anatomical distortion leading to adhesions and fibrosis, as well as endocrine abnormalities and immune disorders. This review discusses the mechanisms …

Published: March 10, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!